Review



iwp4  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    TargetMol iwp4
    Iwp4, supplied by TargetMol, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/iwp4/product/TargetMol
    Average 92 stars, based on 2 article reviews
    iwp4 - by Bioz Stars, 2026-03
    92/100 stars

    Images



    Similar Products

    iwp4  (TargetMol)
    92
    TargetMol iwp4
    Iwp4, supplied by TargetMol, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/iwp4/product/TargetMol
    Average 92 stars, based on 1 article reviews
    iwp4 - by Bioz Stars, 2026-03
    92/100 stars
    		  Buy from Supplier
    iwp4  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc iwp4
    A Schematic illustration of the treatment scheme in iPSCs prior to short-read-NGS RNAseq analysis at day 2 (d2). Timepoint of 2 hours pulse-treatment with 18 nM doxorubicin (Dox) is indicated by a lightning symbol. B Gene concept network of GO-term enrichments and associated downregulated genes of pairwise comparison between Dox-treated iPSCs and the respective control. Number of genes, logFC-value, and GO-terms are listed in the respective legend. C Scheme of iPSC differentiation into iPSC-derived cardiomyocytes (iCMs) following a chemically defined protocol. At defined days (d), cardiac basal media (CBM) was supplemented without B-27 minus insulin (-INS) or with insulin (+INS). In addition, growth factors such as CHIR99021 (CBM-INS1) or <t>IWP4</t> (CBM-INS2) were added at specific days of the differentiation protocol. Days with negative numbers represent the time of culturing iPSCs until initiation of cardiac differentiation. On day 7 differentiation of iPSCs into iPSC-derived cardiomyocytes (iCMs) is completed. Representative images of iCMs acquired with Leica DM IL LED Fluo Cellfactory (Leica). Days (d) of cardiac differentiation are indicated. Magnification: 20x, scale bar: 300 µm. D Determination of sensitivity of iCMs against Dox. iCMs were pulse-treated for 2 hours with increasing doses of doxorubicin (Dox) and viability was determined using an MTT assay. The mean ± SEM of three independent biological replicates (n=3; N=4-8) is shown.
    Iwp4, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/iwp4/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    iwp4 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    wnt inhibitor iwp4  (Biogems International)
    93
    Biogems International wnt inhibitor iwp4
    A Schematic illustration of the treatment scheme in iPSCs prior to short-read-NGS RNAseq analysis at day 2 (d2). Timepoint of 2 hours pulse-treatment with 18 nM doxorubicin (Dox) is indicated by a lightning symbol. B Gene concept network of GO-term enrichments and associated downregulated genes of pairwise comparison between Dox-treated iPSCs and the respective control. Number of genes, logFC-value, and GO-terms are listed in the respective legend. C Scheme of iPSC differentiation into iPSC-derived cardiomyocytes (iCMs) following a chemically defined protocol. At defined days (d), cardiac basal media (CBM) was supplemented without B-27 minus insulin (-INS) or with insulin (+INS). In addition, growth factors such as CHIR99021 (CBM-INS1) or <t>IWP4</t> (CBM-INS2) were added at specific days of the differentiation protocol. Days with negative numbers represent the time of culturing iPSCs until initiation of cardiac differentiation. On day 7 differentiation of iPSCs into iPSC-derived cardiomyocytes (iCMs) is completed. Representative images of iCMs acquired with Leica DM IL LED Fluo Cellfactory (Leica). Days (d) of cardiac differentiation are indicated. Magnification: 20x, scale bar: 300 µm. D Determination of sensitivity of iCMs against Dox. iCMs were pulse-treated for 2 hours with increasing doses of doxorubicin (Dox) and viability was determined using an MTT assay. The mean ± SEM of three independent biological replicates (n=3; N=4-8) is shown.
    Wnt Inhibitor Iwp4, supplied by Biogems International, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/wnt inhibitor iwp4/product/Biogems International
    Average 93 stars, based on 1 article reviews
    wnt inhibitor iwp4 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    iwp4 13954  (Cayman Chemical)
    90
    Cayman Chemical iwp4 13954
    A Schematic illustration of the treatment scheme in iPSCs prior to short-read-NGS RNAseq analysis at day 2 (d2). Timepoint of 2 hours pulse-treatment with 18 nM doxorubicin (Dox) is indicated by a lightning symbol. B Gene concept network of GO-term enrichments and associated downregulated genes of pairwise comparison between Dox-treated iPSCs and the respective control. Number of genes, logFC-value, and GO-terms are listed in the respective legend. C Scheme of iPSC differentiation into iPSC-derived cardiomyocytes (iCMs) following a chemically defined protocol. At defined days (d), cardiac basal media (CBM) was supplemented without B-27 minus insulin (-INS) or with insulin (+INS). In addition, growth factors such as CHIR99021 (CBM-INS1) or <t>IWP4</t> (CBM-INS2) were added at specific days of the differentiation protocol. Days with negative numbers represent the time of culturing iPSCs until initiation of cardiac differentiation. On day 7 differentiation of iPSCs into iPSC-derived cardiomyocytes (iCMs) is completed. Representative images of iCMs acquired with Leica DM IL LED Fluo Cellfactory (Leica). Days (d) of cardiac differentiation are indicated. Magnification: 20x, scale bar: 300 µm. D Determination of sensitivity of iCMs against Dox. iCMs were pulse-treated for 2 hours with increasing doses of doxorubicin (Dox) and viability was determined using an MTT assay. The mean ± SEM of three independent biological replicates (n=3; N=4-8) is shown.
    Iwp4 13954, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/iwp4 13954/product/Cayman Chemical
    Average 90 stars, based on 1 article reviews
    iwp4 13954 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    iwp4  (ReproCELL)
    90
    ReproCELL iwp4
    A Schematic illustration of the treatment scheme in iPSCs prior to short-read-NGS RNAseq analysis at day 2 (d2). Timepoint of 2 hours pulse-treatment with 18 nM doxorubicin (Dox) is indicated by a lightning symbol. B Gene concept network of GO-term enrichments and associated downregulated genes of pairwise comparison between Dox-treated iPSCs and the respective control. Number of genes, logFC-value, and GO-terms are listed in the respective legend. C Scheme of iPSC differentiation into iPSC-derived cardiomyocytes (iCMs) following a chemically defined protocol. At defined days (d), cardiac basal media (CBM) was supplemented without B-27 minus insulin (-INS) or with insulin (+INS). In addition, growth factors such as CHIR99021 (CBM-INS1) or <t>IWP4</t> (CBM-INS2) were added at specific days of the differentiation protocol. Days with negative numbers represent the time of culturing iPSCs until initiation of cardiac differentiation. On day 7 differentiation of iPSCs into iPSC-derived cardiomyocytes (iCMs) is completed. Representative images of iCMs acquired with Leica DM IL LED Fluo Cellfactory (Leica). Days (d) of cardiac differentiation are indicated. Magnification: 20x, scale bar: 300 µm. D Determination of sensitivity of iCMs against Dox. iCMs were pulse-treated for 2 hours with increasing doses of doxorubicin (Dox) and viability was determined using an MTT assay. The mean ± SEM of three independent biological replicates (n=3; N=4-8) is shown.
    Iwp4, supplied by ReproCELL, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/iwp4/product/ReproCELL
    Average 90 stars, based on 1 article reviews
    iwp4 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    iwp4  (Cayman Chemical)
    90
    Cayman Chemical iwp4
    A Schematic illustration of the treatment scheme in iPSCs prior to short-read-NGS RNAseq analysis at day 2 (d2). Timepoint of 2 hours pulse-treatment with 18 nM doxorubicin (Dox) is indicated by a lightning symbol. B Gene concept network of GO-term enrichments and associated downregulated genes of pairwise comparison between Dox-treated iPSCs and the respective control. Number of genes, logFC-value, and GO-terms are listed in the respective legend. C Scheme of iPSC differentiation into iPSC-derived cardiomyocytes (iCMs) following a chemically defined protocol. At defined days (d), cardiac basal media (CBM) was supplemented without B-27 minus insulin (-INS) or with insulin (+INS). In addition, growth factors such as CHIR99021 (CBM-INS1) or <t>IWP4</t> (CBM-INS2) were added at specific days of the differentiation protocol. Days with negative numbers represent the time of culturing iPSCs until initiation of cardiac differentiation. On day 7 differentiation of iPSCs into iPSC-derived cardiomyocytes (iCMs) is completed. Representative images of iCMs acquired with Leica DM IL LED Fluo Cellfactory (Leica). Days (d) of cardiac differentiation are indicated. Magnification: 20x, scale bar: 300 µm. D Determination of sensitivity of iCMs against Dox. iCMs were pulse-treated for 2 hours with increasing doses of doxorubicin (Dox) and viability was determined using an MTT assay. The mean ± SEM of three independent biological replicates (n=3; N=4-8) is shown.
    Iwp4, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/iwp4/product/Cayman Chemical
    Average 90 stars, based on 1 article reviews
    iwp4 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    A Schematic illustration of the treatment scheme in iPSCs prior to short-read-NGS RNAseq analysis at day 2 (d2). Timepoint of 2 hours pulse-treatment with 18 nM doxorubicin (Dox) is indicated by a lightning symbol. B Gene concept network of GO-term enrichments and associated downregulated genes of pairwise comparison between Dox-treated iPSCs and the respective control. Number of genes, logFC-value, and GO-terms are listed in the respective legend. C Scheme of iPSC differentiation into iPSC-derived cardiomyocytes (iCMs) following a chemically defined protocol. At defined days (d), cardiac basal media (CBM) was supplemented without B-27 minus insulin (-INS) or with insulin (+INS). In addition, growth factors such as CHIR99021 (CBM-INS1) or IWP4 (CBM-INS2) were added at specific days of the differentiation protocol. Days with negative numbers represent the time of culturing iPSCs until initiation of cardiac differentiation. On day 7 differentiation of iPSCs into iPSC-derived cardiomyocytes (iCMs) is completed. Representative images of iCMs acquired with Leica DM IL LED Fluo Cellfactory (Leica). Days (d) of cardiac differentiation are indicated. Magnification: 20x, scale bar: 300 µm. D Determination of sensitivity of iCMs against Dox. iCMs were pulse-treated for 2 hours with increasing doses of doxorubicin (Dox) and viability was determined using an MTT assay. The mean ± SEM of three independent biological replicates (n=3; N=4-8) is shown.

    Journal: bioRxiv

    Article Title: Preconditioning of human iPSCs with doxorubicin causes genome-wide transcriptional reprogramming in iPSC-derived cardiomyocytes linked to mitochondrial dysfunction and impaired cardiac regeneration

    doi: 10.1101/2025.04.18.649376

    Figure Lengend Snippet: A Schematic illustration of the treatment scheme in iPSCs prior to short-read-NGS RNAseq analysis at day 2 (d2). Timepoint of 2 hours pulse-treatment with 18 nM doxorubicin (Dox) is indicated by a lightning symbol. B Gene concept network of GO-term enrichments and associated downregulated genes of pairwise comparison between Dox-treated iPSCs and the respective control. Number of genes, logFC-value, and GO-terms are listed in the respective legend. C Scheme of iPSC differentiation into iPSC-derived cardiomyocytes (iCMs) following a chemically defined protocol. At defined days (d), cardiac basal media (CBM) was supplemented without B-27 minus insulin (-INS) or with insulin (+INS). In addition, growth factors such as CHIR99021 (CBM-INS1) or IWP4 (CBM-INS2) were added at specific days of the differentiation protocol. Days with negative numbers represent the time of culturing iPSCs until initiation of cardiac differentiation. On day 7 differentiation of iPSCs into iPSC-derived cardiomyocytes (iCMs) is completed. Representative images of iCMs acquired with Leica DM IL LED Fluo Cellfactory (Leica). Days (d) of cardiac differentiation are indicated. Magnification: 20x, scale bar: 300 µm. D Determination of sensitivity of iCMs against Dox. iCMs were pulse-treated for 2 hours with increasing doses of doxorubicin (Dox) and viability was determined using an MTT assay. The mean ± SEM of three independent biological replicates (n=3; N=4-8) is shown.

    Article Snippet: From day 4 to day 5, 1x B-27 supplement without insulin (ThermoFisher), 50 μg / mL ascorbic acid (Sigma-Aldrich) and 5 μM IWP4 (STEMCELL Technologies Inc.) was added to CBM.

    Techniques: Comparison, Control, Derivative Assay, MTT Assay